Iverson Genetic Diagnostics Release: WARFARIN Study at Franciscan Health System to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin

TACOMA, Wash.--(BUSINESS WIRE)--Iverson Genetic Diagnostics, Inc. announced that the WARFARIN Study (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) was initiated at Franciscan Health System in Tacoma and other major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events. Warfarin, the most commonly prescribed blood thinner worldwide, causes up to 100,000 serious and unnecessary adverse events every year, including thousands of deaths. Studies have shown that DNA testing can dramatically improve the safety and effectiveness of warfarin, with estimated savings to the U.S. healthcare system of approximately $1.1 billion.